These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 9798483)

  • 21. Empirical treatment of influenza-associated pneumonia in primary care: a descriptive study of the antimicrobial susceptibility of lower respiratory tract bacteria (England, Wales and Northern Ireland, January 2007-March 2010).
    Blackburn RM; Henderson KL; Lillie M; Sheridan E; George RC; Deas AH; Johnson AP
    Thorax; 2011 May; 66(5):389-95. PubMed ID: 21357586
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oral pharmacokinetically enhanced co-amoxiclav 2000/125 mg, twice daily, compared with co-amoxiclav 875/125 mg, three times daily, in the treatment of community-acquired pneumonia in European adults.
    Garau J; Twynholm M; Garcia-Mendez E; Siquier B; Rivero A;
    J Antimicrob Chemother; 2003 Nov; 52(5):826-36. PubMed ID: 14563899
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Human serum activity of telithromycin, azithromycin and amoxicillin/clavulanate against common aerobic and anaerobic respiratory pathogens.
    Stein GE; Schooley S; Tyrrell KL; Citron DM; Goldstein EJ
    Int J Antimicrob Agents; 2007 Jan; 29(1):39-43. PubMed ID: 17189093
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Amoxycillin/clavulanic acid--beginning of new era in antibiotic therapy of bacterial infections].
    Iarkin MV
    Antibiot Khimioter; 1998; 43(5):47-8. PubMed ID: 9644525
    [No Abstract]   [Full Text] [Related]  

  • 25. [Study of the bactericide activity of the combination amoxycillin/clavulanic acid and its possible effects in the resistance of beta-lactam drugs].
    Prieto J; Frías J; Alou L; Carcas A
    Med Clin (Barc); 1998 Feb; 110 Suppl 1():12-5. PubMed ID: 9717154
    [No Abstract]   [Full Text] [Related]  

  • 26. Augmentin (amoxicillin/clavulanate) in the treatment of community-acquired respiratory tract infection: a review of the continuing development of an innovative antimicrobial agent.
    White AR; Kaye C; Poupard J; Pypstra R; Woodnutt G; Wynne B
    J Antimicrob Chemother; 2004 Jan; 53 Suppl 1():i3-20. PubMed ID: 14726431
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Role of anaerobic bacteria in community-acquired respiratory pathology].
    Dubreuil L
    Presse Med; 1998 Sep; 27 Suppl 4():10-1. PubMed ID: 9798476
    [No Abstract]   [Full Text] [Related]  

  • 28. Elements of design: the knowledge on which we build.
    MacGowan AP
    Clin Microbiol Infect; 2004 Apr; 10 Suppl 2():6-11. PubMed ID: 14759228
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The clinical pharmacology of amoxicillin and clavulanic acid.
    Reed MD
    Pediatr Infect Dis J; 1998 Oct; 17(10):957-62. PubMed ID: 9802653
    [No Abstract]   [Full Text] [Related]  

  • 30. Comparative in vitro activity of a pharmacokinetically enhanced oral formulation of amoxicillin/clavulanic acid (2000/125 mg twice daily) against 9172 respiratory isolates collected worldwide in 2000.
    Koeth LM; Jacobs MR; Good CE; Bajaksouzian S; Windau A; Jakielaszek C; Saunders KA
    Int J Infect Dis; 2004 Nov; 8(6):362-73. PubMed ID: 15494258
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Sinusal penetration of amoxicillin-clavulanic acid. Formulation 1 g./125 mg., twice daily versus formulation 500 mg./125 mg., three times daily].
    Jehl F; Klossek JM; Peynegre R; Serrano E; Castillo L; Bobin S; Desprez D; Renault C; Neel V; Rouffiac E; Borie C
    Presse Med; 2002 Oct; 31(34):1596-603. PubMed ID: 12426976
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Management of community-acquired pneumopathies of adults in the city and at the hospital].
    Léophonte P
    Presse Med; 1998 Sep; 27 Suppl 4():5-7. PubMed ID: 9798473
    [No Abstract]   [Full Text] [Related]  

  • 33. [Empirical antibacterial therapy of community acquired pneumonia in outpatients].
    Yakovlev SV; Suvorova MP
    Antibiot Khimioter; 1997; 42(10):23-8. PubMed ID: 9412399
    [No Abstract]   [Full Text] [Related]  

  • 34. [Efficacy and tolerance of coamoxiclav in community-acquired lower respiratory tract infections in children].
    Blokhin BM; Aldonina VV; Kozhukhova TM; Nikulin LA; Rumyantsev AG
    Antibiot Khimioter; 1997; 42(10):29-32. PubMed ID: 9412400
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Therapeutic options for pneumococcal pneumonia in Turkey.
    Oncu S; Erdem H; Pahsa A
    Clin Ther; 2005 Jun; 27(6):674-83. PubMed ID: 16117975
    [TBL] [Abstract][Full Text] [Related]  

  • 36. What is optimal antimicrobial therapy for bacteremic pneumococcal pneumonia?
    File TM; Mandell LA
    Clin Infect Dis; 2003 Feb; 36(4):396-8. PubMed ID: 12567295
    [No Abstract]   [Full Text] [Related]  

  • 37. In vitro combined effect of co-amoxiclav concentrations achievable in serum after a 2000/125 mg oral dose, and polymorphonuclear neutrophils against strains of Streptococcus pneumoniae exhibiting decreased susceptibility to amoxicillin.
    Amores R; Alou L; Giménez MJ; Sevillano D; Gómez-Lus ML; Aguilar L; Prieto J
    Int J Antimicrob Agents; 2004 Jul; 24(1):79-82. PubMed ID: 15225866
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Pharmacodynamic assessment of antibiotic sensitivity of Streptococcus pneumoniae].
    Soriano F
    Med Clin (Barc); 1999 Jun; 113(3):103-8. PubMed ID: 10464745
    [No Abstract]   [Full Text] [Related]  

  • 39. [Abscess cellulitis by Streptococcus pneumoniae].
    Salvo S; Durán E; Borrás M; Navarro M; Gil J; Rubio C
    Rev Esp Quimioter; 2010 Dec; 23(4):213-4. PubMed ID: 21191562
    [No Abstract]   [Full Text] [Related]  

  • 40. Does the degree of penicillin susceptibility of Streptococcus pneumoniae affect the bactericidal activity of co-amoxiclav versus oral cephalosporins at physiological concentrations? An in vitro pharmacodynamic simulation.
    Prieto J; Giménez MJ; Balcabao IP; Gómez-Lus ML; Aguilar L
    J Chemother; 1999 Oct; 11(5):345-8. PubMed ID: 10632379
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.